Eltrombopag is a hematological drug used to treat thrombocytopenia, a condition characterized by a low platelet count. It is an oral thrombopoietin receptor agonist, which stimulates the production of platelets in the bone marrow. Eltrombopag is used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) and in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy. It is also used to reduce the need for platelet transfusions in patients with SAA. Eltrombopag is marketed by Novartis under the brand name Promacta, and by GlaxoSmithKline under the brand name Revolade. Other companies involved in the market include Teva Pharmaceuticals, which markets the generic version of the drug, and Shire, which markets the drug under the brand name Doptelet. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
